Abstract:Objective To investigate the percentages of CD4+T and CD8+T cells in the peripheral blood and serum cytokine levels (IL-6, IL-10, IFN-γand TNF-α) in patients with chronic hepatitis B virus (HBV) infection during different immune status and explore the association between the percentages of T cell subsets and HBeAg seroconversion. Methods Seventy-nine patients with chronic HBV infection as well as 21 healthy donors were enrolled in this study. Blood samples were collected for detecting the percentages of CD4+T and CD8+T cells by lfow cytometry. Thirty-three HBeAg positive CHB patients received antiviral treatment were successfully followed for 48 weeks. At the end of 48 weeks, 7 of 33 HBeAg positive CHB paitents achieved HBeAg seroconversion. The percentages of CD4+T and CD8+T cells were detected at ifve time points of antivirus treatment:T1 (4 week), T2 (8 week), T3 (12 week), T4 (24 week) and T5 (48 week). Serum cytokine levels were also detected by cytometric bead array (CBA). Results As compared with normal controls, the percentage of CD4+T cell and the ratio of CD4+/CD8+were lower in patients in the immune reactive phase (P all<0.05). However, the percentage of CD8+T cell was higher than normal controls (F=3.610, P<0.05). During the same monitoring period, the HBV DNA loads and ALT levels in patients who achieved HBeAg seroconversion decreased signiifcantly compared with patients without HBeAg seroconversion. Besides, the increase of CD8+T cells duing the periodΔT0-T1 andΔT0-T2 and the increase of CD4+T cells during periodΔT0-T5 were signiifcantly different between HBeAg seroconversion patients and HBeAg non-seroconversion patients (Z=-2.200, P<0.05). The cytokine levels of IL-10 and IFN-γin patients of immune reactive phase were higher than health controls and patients in immune tolerant phase (P all<0.05). The cytokine levels of IL-10 decreased signiifcantly at 12 weeks (T3) and 24 weeks (T4) of antiviral treatment (t=3.037 and 3.180, P all<0.05) and were positively correlated with the HBV DNA loads and ALT levels. Conclusions The percentages of CD4+T and CD8+T cell and serum cytokine levels were changed in different immune status of chronic HBV infection. The increase of CD8+T cell and CD4+T cell percentage during the process of antiviral treatment with HBeAg positive CHB patients were associated with high HBeAg seroconversion rate.

Distinct T‐cell receptor profiles associated with hepatitis B e antigen seroconversion during entecavir treatment

Complementarity-Determining Region 3 Size Spectratypes of T Cell Receptor Β Chains in CD8 + T Cells Following Antiviral Treatment of Chronic Hepatitis B

The Frequency and Skewed T-Cell Receptor Beta-Chain Variable Patterns of Peripheral Cd4(+)Cd25(+) Regulatory T-Cells Are Associated with Hepatitis B E Antigen Seroconversion of Chronic Hepatitis B Patients During Antiviral Treatment

Circulating Chemokine (C-X-C Motif) Receptor 5+CD4+T Cells Benefit Hepatitis B E Antigen Seroconversion Through IL-21 in Patients with Chronic Hepatitis B Virus Infection

Seroconversion Through IL-21 in Patients with Chronic HBV Infection

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B

Characteristics of T-cell subsets and serum cytokines in patients with chronic hepatitis B during different immune status and after antivirus treatment

[Relationship Between PD-1 Expression on Peripheral T Lymphcytes and HBeAg Seroconversion after Entecavir Treatment in Chronic Hepatitis B Patients].

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B

Dynamic Metabolic Profiles for HBeAg Seroconversion in Chronic Hepatitis B (CHB) Patients by Gas Chromatography-Mass Spectrometry (GC-MS)

Functional study on plasmacytoid dendritic cells in patients with HBeAg-positive chronic hepatitis B treated with entecavir

Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects

Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients

Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection

Clinical efficacy of traditional Chinese medicine combined with entecavir in chronic hepatitis B patients